|
Diffuse Large B-Cell Lymphoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Inhibition of SYK or BTK augments venetoclax sensitivity in SHP1-negative/BCL-2-positive diffuse large B-cell lymphoma.
|
30872780 |
2019 |
|
Diffuse Large B-Cell Lymphoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Chronic activation of the Bruton's tyrosine kinase (BTK)-mediated B-cell receptor (BCR) signaling is a hallmark of many B-cell lymphoid malignancies, including chronic lymphocytic leukemia (CLL) and diffuse large B-cell lymphoma (DLBCL).
|
31801949 |
2019 |
|
Diffuse Large B-Cell Lymphoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Currently, Bruton tyrosine kinase (BTK) inhibitor (ibrutinib) is one of the most promising medicine in clinical trials for DLBCL, to which about 25% of patients with relapsed or refractory DLBCL are responsive.
|
30907011 |
2019 |
|
Diffuse Large B-Cell Lymphoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
<b>Expert opinion</b>: Incorporation of novel therapies such as immunomodulatory agents and Bruton tyrosine kinase (BTK) inhibitors in the treatment of higher-risk DLBCL subgroups have shown to be effective; however, confirmatory data are required to change the standard of care.
|
30884247 |
2019 |
|
Diffuse Large B-Cell Lymphoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Further co‑immunoprecipitation studies demonstrated that MYD88 bound to BTK in L265P‑DLBCL cells, and that this binding was abrogated following ST2825 treatment.
|
31432184 |
2019 |
|
Diffuse Large B-Cell Lymphoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Here, for the first time, we investigate whether the combination of PKCβ inhibitor enzastaurin and BTK inhibitor ibrutinib has synergistic anti-tumor effects in DLBCL.
|
30777096 |
2019 |
|
Diffuse Large B-Cell Lymphoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
In vivo activity of AQX-435, alone or in combination with the BTK inhibitor ibrutinib, was assessed using DLBCL cell line and patient-derived xenograft models.
|
31831562 |
2019 |
|
Diffuse Large B-Cell Lymphoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Inhibition of the Bruton's tyrosine kinase (BTK), a BCR downstream target, is therapeutically effective only in a subgroup of patients with DLBCL.
|
29567799 |
2018 |
|
Diffuse Large B-Cell Lymphoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
The CK2 inhibitor acted synergistically with either the SYK inhibitor Fostamatinib or the BTK inhibitor Ibrutinib in inducing DLBCL cell death.
|
28460620 |
2018 |
|
Diffuse Large B-Cell Lymphoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
We therefore engineered BTK<sup>Cys481Ser</sup> and BTK<sup>WT</sup> expressing MYD88-mutated Waldenström macroglobulinemia (WM) and activated B-cell (ABC) diffuse large B-cell lymphoma (DLBCL) cells and observed reactivation of BTK-PLCγ2-ERK1/2 signaling in the presence of ibrutinib in only the former.
|
29496671 |
2018 |
|
Diffuse Large B-Cell Lymphoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
However, responses of the diffuse large B-cell lymphoma (DLBCL) to inhibitors of BTK (BTKi) are infrequent, highlighting the need to identify mechanisms of resistance to BTKi as well as predictive biomarkers.
|
29690649 |
2018 |
|
Diffuse Large B-Cell Lymphoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Predicted NF-κB activating mutations were downstream of BTK and IRAK, and many overlapped with somatic mutations found in diffuse large B-cell lymphoma.
|
30401751 |
2018 |
|
Diffuse Large B-Cell Lymphoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
The Bruton tyrosine kinase inhibitor ibrutinib demonstrates single-agent activity in rel/ref DLBCL, particularly of non-germinal center (non-GC) cell of origin.
|
29386196 |
2018 |
|
Diffuse Large B-Cell Lymphoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Compound 28 was shown to be capable of demonstrating inhibition of NF-κB activation and growth of the ABC subtype of DLBCL cell lines in vitro at high concentrations but showed greater effects in combination with a BTK inhibitor at lower concentrations.
|
29172502 |
2017 |
|
Diffuse Large B-Cell Lymphoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
PI3Kδ inhibitor idelalisib in combination with BTK inhibitor ONO/GS-4059 in diffuse large B cell lymphoma with acquired resistance to PI3Kδ and BTK inhibitors.
|
28178345 |
2017 |
|
Diffuse Large B-Cell Lymphoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma are the most prevalent B-lymphocyte neoplasms in which abnormal activation of the Bruton tyrosine kinase (BTK)-mediated B-cell receptor signaling pathway contributes to pathogenesis.
|
28428442 |
2017 |
|
Diffuse Large B-Cell Lymphoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
While selective inhibition of BTK with ibrutinib causes clinical responses in relapsed DLBCL patients, most responses are partial and of a short duration.
|
28352655 |
2017 |
|
Diffuse Large B-Cell Lymphoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Strong synergism was observed with pimasertib combined with the PI3K inhibitor idelalisib and the BTK inhibitor ibrutinib in cell lines derived from diffuse large B-cell lymphoma (DLBCL) and mantle cell lymphoma.
|
26961147 |
2016 |
|
Diffuse Large B-Cell Lymphoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Combinatorial BTK and MALT1 inhibition augments killing of CD79 mutant diffuse large B cell lymphoma.
|
26540570 |
2015 |
|
Diffuse Large B-Cell Lymphoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Pharmacological or dominant-negative JNK inhibition restricts DLBCL survival in vitro and in vivo and synergizes strongly with the Bruton's tyrosine kinase inhibitor ibrutinib.
|
25847947 |
2015 |
|
Diffuse Large B-Cell Lymphoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Synergistic induction of apoptosis by combination of BTK and dual mTORC1/2 inhibitors in diffuse large B cell lymphoma.
|
24970801 |
2014 |
|
Diffuse Large B-Cell Lymphoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
The erythroleukemia cell line K-562, the promyelocytic line HL-60 and the histiocytic lymphoma line U-937 were found to have BTK mRNA levels comparable to B cells.
|
8283037 |
1994 |